3. Covidien plc (NYSE: COV ) This health care company boasts leading market positions across its product portfolio. Covidien operates three divisions — medical devices (which represents 68% of sales), pharmaceuticals (17% of sales), and medical supplies (15% of sales). The company will spin off its pharmaceutical business in mid-2013 and focus on the faster-growing, higher-margin medical device industry.